Rep. Maria Elvira Salazar Acquires Shares of Moderna, Inc. (NASDAQ:MRNA)

Key Points

• Rep. Maria Elvira Salazar disclosed purchasing $1,001–$15,000 of Moderna shares on August 19 in her UBS IRA account, while also reporting a sale of Moderna shares in the same value range and date.
• Moderna shares opened at $136.62, up 0.7%, after reporting quarterly revenue of $145 million and an adjusted loss of $1.97 per share, slightly better than analyst expectations.
• Wall Street’s consensus rating remains Hold, with an average price target of $76.72, despite several analysts raising targets and institutional investors holding 75.33% of the company.

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Moderna, Inc. NASDAQ: MRNA. In a filing disclosed on September 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on August 19th. The trade occurred in the Representative's "UBS IRA ACCOUNT" account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 8/24/2026.
• Sold $1,001 - $15,000 in shares of Moderna NASDAQ: MRNA on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Qualcomm NASDAQ: QCOM on 8/19/2026.
• Purchased $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 8/19/2026.
• Sold $15,001 - $50,000 in shares of Chubb NYSE: CB on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Qualcomm NASDAQ: QCOM on 8/12/2026.
• Purchased $1,001 - $15,000 in shares of SpaceX NASDAQ: SPCX on 8/12/2026.
• Purchased $1,001 - $15,000 in shares of Berkshire Hathaway NYSE: BRK.B on 8/7/2026.
• Purchased $1,001 - $15,000 in shares of Berkshire Hathaway NYSE: BRK.B on 7/28/2026.
• Purchased $15,001 - $50,000 in shares of Berkshire Hathaway NYSE: BRK.B on 7/28/2026.

Moderna Trading Up 0.7%

NASDAQ:MRNA opened at $136.62 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The firm has a market capitalization of $54.54 billion, a price-to-earnings ratio of -17.10 and a beta of 1.10. Moderna, Inc. has a one year low of $22.28 and a one year high of $176.66. The business has a fifty day moving average price of $91.07 and a 200-day moving average price of $66.19.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.Moderna's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.13) earnings per share. Sell-side analysts forecast that Moderna, Inc. will post -6.09 EPS for the current year.

Institutional Trading of Moderna

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Moderna in the 2nd quarter worth approximately $2,142,877,000. California State Teachers Retirement System raised its position in shares of Moderna by 6,698.1% during the second quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company's stock valued at $1,938,523,000 after buying an additional 27,274,128 shares during the last quarter. Capital World Investors bought a new stake in shares of Moderna during the fourth quarter valued at approximately $378,299,000. Invesco Ltd. lifted its holdings in shares of Moderna by 15.7% in the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company's stock worth $212,223,000 after buying an additional 1,115,131 shares in the last quarter. Finally, Theleme Partners LLP bought a new position in shares of Moderna during the second quarter worth $564,272,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Moderna from $40.00 to $77.00 and gave the company an "underweight" rating in a research report on Friday, August 21st. Morgan Stanley increased their target price on shares of Moderna from $39.00 to $89.00 and gave the stock an "equal weight" rating in a report on Thursday, August 20th. Barclays raised their target price on shares of Moderna from $48.00 to $125.00 and gave the stock an "equal weight" rating in a research note on Monday, August 24th. Brookline Capital Markets reaffirmed a "buy" rating on shares of Moderna in a report on Wednesday, August 19th. Finally, CLSA upgraded shares of Moderna to an "outperform" rating in a research report on Friday, August 28th. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $76.72.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the sale, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 10.80% of the company's stock.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida's 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida's 27th Congressional District. She won in the general election on November 5, 2024. Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Moderna

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.